Interpreting Clinical Data to Guide Coverage Decisions for Rare Disease Therapies

EP: 1.Overview of Gene Therapy Approaches and Impacts

EP: 2.Key Factors in Gene Vector Selection

EP: 3.Viral Vectors in Gene Therapy

EP: 4.Navigating Gene Therapy Eligibility: The Role of Genetic Testing

EP: 5.Evaluating Transformative Gene Therapies

EP: 6.Shifting the Treatment Paradigm in Spinal Muscular Atrophy

EP: 7.Developments in Muscular Dystrophy Gene Therapy

EP: 8.Review of Clinical Evidence for Delandistrogene Moxeparvovec for DMD

EP: 9.Driving Clinical Insights: Harnessing Functional Assessments in DMD Research

EP: 10.Duchenne Muscular Dystrophy Treatment Landscape Review

EP: 11.Strategic Insights Into Evolving Gene Therapy Trends

EP: 12.Sustainable Gene Therapy Coverage Approaches

Now Viewing

EP: 13.Interpreting Clinical Data to Guide Coverage Decisions for Rare Disease Therapies

EP: 14.Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect

EP: 15.Innovative Payment Models for Gene Therapies

EP: 16.Ethical Implications of Patient Access Restrictions

EP: 17.Enhancing Collaboration for Patient-Centered Care in Rare Diseases

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Jessica Nance, MD, MS; Kimberly C. Chen, DO, MSHLM; Emma Ciafaloni, MD, FAAN; and Mary Pak, MD, FACP.

Haumschild moderates a conversation on the intricacies of interpreting clinical data and influencing coverage decisions for rare disease therapies with Ciafaloni and Pak. Ciafaloni highlights challenges in clinical trial design and outcome measurement, emphasizing the need for nuanced approaches to address the diverse spectrum of rare diseases. She discusses the evolving landscape of outcome measures, including wearable devices, to capture meaningful clinical improvements. Pak, drawing from her perspective as a managed care executive, explores the factors influencing coverage decisions, such as safety, efficacy, and cost-effectiveness. She underscores the importance of evidence-based coverage criteria while acknowledging the need for flexibility in evaluating therapy effectiveness across patient populations. The discussion underscores the delicate balance between strict trial inclusion criteria and real-world patient needs, emphasizing collaboration among stakeholders to optimize patient access to life-saving therapies while ensuring prudent resource allocation. Haumschild concludes by acknowledging the ongoing challenges in navigating clinical and coverage complexities for rare disease therapies and the importance of continued dialogue and collaboration to address these challenges effectively.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.